Nanobiotix Reports Q1 2025 Achievements and Financial Status

Nanobiotix has announced significant progress in its operational and financial activities during the first quarter of 2025. The company successfully dosed its first patient in the CONVERGE Phase 2 clinical trial targeting unresectable stage 3 non-small cell lung cancer (NSCLC). Moreover, novel data from Phase 1 studies involving JNJ-1900 (NBTXR3) were presented at the European Lung Cancer Conference, illustrating encouraging safety and early efficacy signs.

Financially, Nanobiotix enhanced its position by amending the global licensing agreement for JNJ-1900, thus extending its cash runway to mid-2026 with significant reductions in operational cash burn. The company reported cash reserves of €39.8 million as of March 31, 2025, ensuring continued operations well into the next year.

Nanobiotix's ongoing collaboration and development efforts in pivotal cancer treatment areas underscore its commitment to advancing therapeutic options for patients.